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Abstract
Background: Levels or fluctuations in the partial pressure of 
CO2 (PCO2) may affect outcomes for extremely low birth 
weight infants. Objectives: In an exploratory analysis of a 
randomized trial, we hypothesized that the PCO2 values 
achieved could be related to significant outcomes. Meth-
ods: On each treatment day, infants were divided into 4 
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groups: relative hypocapnia, normocapnia, hypercapnia, or 
fluctuating PCO2. Ultimate assignment to a group for the 
purpose of this analysis was made according to the group 
in which an infant spent the most days. Statistical analyses 
were performed with analysis of variance (ANOVA), the 
Kruskal-Wallis test, the χ2 test, and the Fisher exact test as 
well as by multiple logistic regression. Results: Of the 359 
infants, 57 were classified as hypocapnic, 230 as normocap-
nic, 70 as hypercapnic, and 2 as fluctuating PCO2. Hypercap-
nic infants had a higher average product of mean airway 
pressure and fraction of inspired oxygen (MAP × FiO2). 
For this group, mortality was higher, as was the likelihood 
of having moderate/severe bronchopulmonary dysplasia 
(BPD), necrotizing enterocolitis (NEC), and poorer neurode-
velopment. Multiple logistic regression analyses showed an 
increased risk for BPD or death associated with birth weight 
(p < 0.001) and MAP × FiO2 (p < 0.01). The incidence of ad-
verse neurodevelopment was associated with birth weight 
(p < 0.001) and intraventricular hemorrhage (IVH; p < 0.01). 
Conclusions: Birth weight and respiratory morbidity, as 
measured by MAP × FiO2, were the most predictive of death 
or BPD and NEC, whereas poor neurodevelopmental out-
come was associated with low birth weight and IVH. Uni-
variate models also identified PCO2. Thus, hypercapnia 
seems to reflect greater disease severity, a likely contributor 
to differences in outcomes. © 2018 S. Karger AG, Basel
Introduction
Carbon dioxide, aside from being a byproduct of en-
ergy metabolism, is an important regulator for vascular 
tone and blood pH. In healthy subjects, the partial pres-
sure of carbon dioxide (PCO2) is controlled by spontane-
ous respiration to keep the pH close to 7.4, a level nor-
mally achieved with a PCO2 of 40 mm Hg. Metabolic ab-
normalities that shift pH levels result in physiological 
alterations to respiratory drive and thus PCO2. Further-
more, changing PCO2 also affects kidney function, as bi-
carbonate is retained to move pH levels back to the phys-
iological norm of 7.4. The effects of PCO2 on organ func-
tion and perfusion differ from organ to organ. A higher 
PCO2 (i.e., >40 mm Hg), may provide some protection 
for the myocardium [1] and increase pulmonary vascular 
tone, thus increasing pulmonary arterial pressure [2]. At 
the same time, central nervous system vascular tone is 
decreased, leading to brain hyperperfusion [3, 4], which 
may increase cerebral perfusion and oxygen delivery to 
the brain but also increases the risk of intraventricular 
hemorrhage (IVH) in very preterm infants, where ex-
treme values have the greatest importance [5, 6]. At a low 
PCO2, brain perfusion is reduced and blood supply to the 
brain may become compromised, possibly even resulting 
in cerebral palsy in newborns [4, 7]. Furthermore, PCO2 
affects the electrical activity of the brain [4, 8].
Important cellular functions are also influenced by 
PCO2. Various animal models have demonstrated either 
protective or harmful effects. Lung epithelial cell mem-
brane repair [9] and vectorial epithelial ion transport (al-
veolar fluid clearance) [10] were impaired by higher 
PCO2 in in vitro models. Furthermore, young rats devel-
oped retinopathy when exposed to very high PCO2 values 
(of approx. 100 mm Hg) [11]. Neuronal cells may be less 
susceptible in this aspect, but data on this are sparse.
Extremely preterm infants who survive intensive care 
are at a high risk of developmental abnormalities involv-
ing various organs, including the lungs, central nervous 
system, kidneys, and digestive system [12, 13]. Given its 
broad-ranging effects on various tissues, alterations in 
PCO2 may have lasting effects on organ functions later in 
life [14].
In a recently completed clinical multicenter trial, in-
fants were randomly allocated to 2 different PCO2 target 
ranges [15]. Although both target ranges were in the hy-
percapnic range, there were distinct differences between 
them. Regardless of the randomized target group to which 
they were assigned, infants had a marked influence on 
PCO2 levels through their own respiratory drive, matu-
rity, and degree of lung disease, and did not always re-
main within the target range to which they had been as-
signed. This resulted in a considerable overlap in actual 
PCO2 values between the study groups. Although the ran-
domized assignment to a target group did not significant-
ly influence important clinical outcomes, there were 
trends suggesting that the higher target range could be 
associated with an increased risk of bronchopulmonary 
dysplasia (BPD) and necrotizing enterocolitis (NEC) 
[15], but does not affect neurodevelopment [16]. Effects 
such as these may be more evident in analyses based on 
actual PCO2 values rather than on the prescribed target 
ranges.
Extensive data on blood gas analyses and important 
clinical outcomes were collected during the trial [15]. We 
sought to determine whether PCO2 during the first 2 
weeks of life may influence the short- and long-term 
health of preterm infants. We hypothesized that different 
PCO2 trajectories might be associated with different rates 
of adverse outcomes.
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Methods
Patient Allocation 
Inborn infants with a gestational age of 23(0/7)–28(6/7) weeks, 
weighing 400–1,000 g and receiving endotracheal intubation and 
mechanical ventilation within 24 h of birth, were enrolled within 
36 h of birth into the Permissive Hypercapnia in Extremely Low 
Birth Weight Infants (PHELBI) trial at 16 tertiary care perinatal 
centers in Germany between March 2008 and July 2012 [15]. Each 
center’s institutional review board approved the trial and written 
informed consent was obtained from the parents or legal guardians 
of all of the infants.
The infants were randomly allocated to 2 different PCO2 target 
ranges. These target ranges increased age-dependently in both 
groups to facilitate weaning, and were applied for the first 14 days 
of life or until extubation. A detailed description of the trial proto-
col has been published previously [15].
PCO2 Variables
This data analysis was based on the actual PCO2 values ob-
tained by blood gas analyses during the first 14 days of life, rather 
than on the group to which infants were randomly assigned.
Infants were categorized into 4 groups according to their PCO2 
values, relative to those of other infants in the study. Because of 
their higher impact on outcome, the extreme PCO2 values of each 
infant were used for assignment to a group, similar as in previous 
analyses [17, 18]. Every treatment day, the maximum PCO2 values 
achieved by all infants were ranked into 4 quartiles. The same was 
done with the minimum PCO2 values. Infants whose minimum 
PCO2 was in the lowest quartile of the minimal quartiles but whose 
maximum PCO2 did not reach the highest maximal quartile were 
defined as “hypocapnic.” Infants whose minimum PCO2 was not 
in the lowest minimal quartile but whose maximum PCO2 was in 
the highest maximal quartile were defined as “hypercapnic.” In-
fants whose minimum PCO2 was in the lowest minimal quartile 
and whose maximum PCO2 was in the highest maximal quartile 
were defined as “fluctuating,” and the remainder, whose PCO2 lev-
els reached neither the lowest minimal nor highest maximal quar-
tile, were considered “normocapnic.” Assignment to a group for 
the purpose of data analysis was done on the basis of the category 
in which the infant spent the most days, and in the event of an 
equal number of days being spent in 2 categories, more weight was 
given to the earlier days.
We also calculated maximum, minimum, and time-weighted 
average PCO2 exposure. Severity of lung disease was assessed by 
the product of mean airway pressure (MAP) and fraction of in-
spired oxygen (FiO2).
Outcome Assessments
BPD was defined as requiring mechanical pressure support or 
supplemental oxygen at 36 weeks ± 2 days postmenstrual age, in-
cluding an O2 reduction test for infants requiring an FiO2 <0.3 
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Fig. 1. Daily PCO2 distributions of the 3 
groups, shown as box-and-whisker plots. 
a Days 1–7. b Days 8–14. Boxes, 25th–75th 
percentile; whiskers, minimum – maxi-
mum. Inside the boxes, horizontal lines 
represent median values and asterisks rep-
resent mean values. White boxes, relatively 
hypocapnic group; light grey boxes, nor-
mocapnic group; darker grey boxes, rela-
tively hypercapnic group. The shaded areas 
in the background indicate the PCO2 target 
ranges of the former randomized trial [15].
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[19]. This also represents moderate-to-severe BPD according to 
the National Institute of Child Health and Development consensus 
definition [20]. The incidence and severity of IVH were assessed 
according to the method of Papile et al. [21], by cranial ultrasound 
assessed by a single pediatric radiologist on the first day of life, at 
12–14 days, and at 36 weeks postmenstrual age. Retinopathy of 
prematurity (ROP) was routinely screened and classified accord-
ing to the international classification [22]. NEC was diagnosed 
when the clinical and radiological findings corresponded to stage 
II or higher according to the criteria of Bell et al. [23]. A ductus 
arteriosus was considered persistent if it persisted throughout the 
period of hospitalization or if it needed to be ligated after medical 
treatment failed. The Clinical Risk Index for Babies (CRIB) score 
was also determined [24].
All surviving infants were invited to a neurodevelopmental fol-
low-up examination at 2 years ± 3 months corrected age [16]. The 
mental developmental index (MDI) and the psychomotor devel-
opmental index (PDI) were determined using the Bayley Scales of 
Infant Development II (German translation) [25]. Neurodevelop-
mental impairment was defined as either MDI <70 or PDI <70 or 
hearing or visual impairments. Furthermore, motor function was 
assessed by the modified Gross Motor Function Classification Sys-
tem (GMFCS), with scores ranging from level 0 (normal) to level 
5 (the most impaired) [26]. Parent perception was assessed by the 
EFkE (Elternfragebogen zur kindlichen Entwicklung) question-
naire [27, 28], a validated German translation of the Child Devel-
opment Inventory (CDI) [29].
Statistical Considerations
Statistical tests included the ANOVA, Kruskal-Wallis, χ2, and 
Fisher exact tests as appropriate. All analyses have to be considered 
as secondary and hypothesis-generating since this investigation 
was not based on a randomized intervention. Adjustments for mul-
tiple testing were not done. A p value of <0.05 was considered sig-
nificant. Univariate logistic regression analyses were performed to 
identify possible risk factors for adverse outcomes, including min-
imal, maximal, and average PCO2 exposure, and the PCO2 standard 
deviation. The adverse outcomes tested were mortality, BPD, ROP, 
NEC, severe IVH, MDI <70/PDI <70, neurodevelopmental impair-
ment, or the end points mentioned combined with death. Risk fac-
tors that yielded significant differences in univariate analyses were 
fed into multiple logistic regression to determine which conditions 
constituted independent risk factors. SAS software v9.4 (SAS Insti-
tute, Cary NC, USA) was used throughout. The trial, from which 
these data were derived, was approved by the institutional review 
board of each center and registered as ISRCTN56143743.
Results
Of the 359 infants enrolled, 311 survived, and 265 of 
these participated in the follow-up exam. The remaining 
46 were lost to follow-up for various reasons [16]. Demo-
graphic characteristics and clinical data up to discharge 
did not differ for infants with and without follow-up [16].
Table 1. Comparative demographic data, overall and by PCO2 category
All infants
(n = 359)
Hypocapnic 
(n = 57, 16%)
Normocapnic
(n = 230, 64%)
Hypercapnic
(n = 70, 19%)
p 
Gestational age, weeks§ 25(4/7)±1(2/7) 25(6/7)±1(3/7) 25(5/7)±1(2/7) 25(2/7)±1(3/7) 0.06
Birth weight, g§ 711 ± 154 690 ± 173 724 ± 147 690 ± 158 0.14
Male 204 (57) 27 (47) 130 (57) 46 (66) 0.11
Antenatal steroids (any) 319 (89) 51 (90) 203 (88) 63 (90) 0.91
PPROM >24 h 80 (22) 16 (28) 49 (21) 15 (21) 0.54
5-min Apgar‡ 8 (1 – 10) 8 (4 – 10) 8 (1 – 10) 8 (1 – 10) 0.49
Surfactant† 347 (97) 55 (97) 222 (97) 68 (97) 1.00
First randomized into the high
target group 179 (50) 25 (44) 99 (43) 53 (76) <0.01
PDA 52 (15) 7 (13) 26 (11) 17 (27) <0.01
Methylxanthine therapy† 337 (94) 54 (95) 220 (96) 62 (89) 0.10
VTe, mL/kg§ 5.44 ± 1.85 (n = 204) 5.72 ± 1.70 (n = 25) 5.45 ± 1.94 (n = 129) 5.38 ± 1.65 (n = 48) 0.75
PCO2, mm Hg§ 51 ± 7 43 ± 5 50 ± 4 60 ± 4 <0.01
pH§ 7.28 ± 0.06 7.32 ± 0.05 7.29 ± 0.05 7.23 ± 0.05 <0.01
MAP × FiO2‡ 1.89 (0.82 – 16.91) 1.50 (0.85 – 9.28) 1.83 (0.82 – 16.91) 2.73 (1.39 – 11.25) <0.01
CRIB score‡ 7 (1, 4, 8, 16) 7 (1, 4, 9, 16) 6 (1, 4, 8, 15) 8 (1, 5, 9, 14) <0.01
Two infants with mainly fluctuating PCO2 values were not assigned to any group. They received no prenatal steroids and were ini-
tially randomized into the hypercapnic arm of the trial. Their MAP × FiO2 values were 3.45 and 5.89, and their CRIB scores were 9 
and 10. 
Unless otherwise specified, data are given as: number of infants (%), χ2 test. § Mean ± SD, 1-way ANOVA. † The Fisher exact test. 
‡ Median (range), and for the CRIB score: median (minimum, 1st quartile, 3rd quartile, maximum), Kruskal-Wallis test. 
PPROM, preterm premature rupture of membranes; PDA, patent ductus arteriosus; VTe, expiratory tidal volume; CRIB, Clinical 
Risk Index for Babies.
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The majority of infants (64%) were classified as nor-
mocapnic, 16% were hypocapnic, and 19% were hyper-
capnic. Two infants were classified on most days as fluc-
tuating, so we decided to not consider them and to per-
form the data analysis with 3 groups only. The daily PCO2 
ranges of the 3 groups are shown in Figure 1.
The baseline characteristics of infants in all 3 groups 
were similar (Table 1). Aside from higher PCO2 and low-
er pH levels, hypercapnic infants had higher MAP × FiO2, 
higher CRIB scores, and were more likely to have a patent 
ductus arteriosus (PDA). Tidal volumes were not statisti-
cally different between groups. Most infants in the hyper-
capnic group had initially been randomized into the hy-
percapnic arm of the main trial, but there was a consider-
able overlap with the other groups. 
Hypercapnic infants had significantly higher mortality 
and incidence of moderate-to-severe BPD, were more 
likely to have received postnatal hydrocortisone and to 
develop NEC, and gained less weight (Table 2). 
Interestingly, hypocapnic infants were less likely to 
have an IVH, when compared with all other groups. 
There also appeared to be a relationship between neu-
rodevelopmental outcomes and PCO2 group (Table  3). 
Hypercapnic infants had significantly lower MDI scores 
and were more likely to have an MDI <70 and cerebral 
palsy by GMFCS scores (≥2). Their weight and height 
gains were lower. The PDI results, in contrast, were not 
affected. Furthermore, there were strong associations 
between the CRIB scores and major outcome variables 
(Table 4).
In the multiple logistic analyses, moderate-to-severe 
BPD or death was related to birth weight and MAP × FiO2 
(Table 5). The combined outcome, BPD/IVH/death, was 
only associated with MAP × FiO2 (Table 6). Low MDI 
scores were associated with birth weight and IVH (Ta-
ble 7) whereas low PDI scores were strongly associated 
with IVH (Table 8). 
The outcome of the 2 mainly fluctuating infants was 
poor, despite the absence of a severe IVH. One died and 
the other survived with severe BPD and neurodevelop-
mental impairment, and did not achieve MDI and PDI 
scores >49.
Table 2. Comparative clinical outcome data, overall and by PCO2 category
All infants
(n = 359)
Hypocapnic 
(n = 57, 16%)
Normocapnic
(n = 230, 64%)
Hypercapnic
(n = 70, 19%)
p
Mortality until 36 weeks PMA 44 (12) 7 (12) 17 (7) 19 (27)
<0.01Moderate-to-severe BPD 75 (21) 10 (18) 42 (18) 22 (31)
Moderate-to-severe BPD or death 119 (33) 17 (30) 59 (26) 41 (59)
BPD (cons. def.) mild† 216 (60) 35 (61) 153 (67) 28 (40)
<0.01BPD (cons. def.) moderate† 41 (11) 7 (12) 23 (10) 11 (16)
BPD (cons. def.) severe† 34 (10) 3 (5) 19 (8) 11 (16)
Mortality until day 14§ 28 (8) 7 (12) 10 (4) 11 (16) <0.01
IVH (all grades) 104 (29) 10 (18) 73 (32) 20 (29) <0.01
Severe IVH (grade 3 – 4) 47 (13) 7 (12) 29 (13) 11 (16) 0.01
Periventricular leukomalacia 27 (8) 5 (9) 15 (7) 6 (9) 0.76
Hydrocephalus internus 51 (17) 7 (15) 33 (16) 11 (22) 0.59
Hydrocephalus internus with shunt† 14 (4) 1 (2) 11 (5) 2 (3) 0.67
Postnatal steroids (any) 131 (36) 13 (23) 83 (36) 33 (47) 0.01
Postnatal dexamethasone 59 (17) 9 (16) 35 (15) 14 (21) 0.55
Postnatal hydrocortisone 88 (25) 6 (11) 55 (24) 25 (37) <0.01
Retinopathy of prematurity 156 (47) 26 (50) 104 (47) 25 (46) 0.88
Severe retinopathy ≥ grade 3 46 (14) 6 (12) 30 (14) 10 (18) 0.57
Necrotizing enterocolitis ≥2† 28 (8) 6 (11) 12 (5) 9 (14) 0.04
Weight at 36 weeks PMA, g‡ 1,958 ± 350 (313) 1,892 ± 310 (50) 1,997 ± 353 (211) 1,869 ± 353 (52) 0.02
The 2 infants with mainly fluctuating PCO2 values were not assigned to any group; one died and the other survived with severe BPD. 
BPD corresponds to moderate or severe BPD according to the consensus definition (cons. def.) [20].
Unless otherwise specified, data are given as: number of infants (%), χ2 test. † The Fisher exact test. ‡ Mean ± SD (n of patients contrib-
uting data), 1-way ANOVA. # These infants died before the final IVH grading was done.
PMA, postmenstrual age.
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Table 3. Comparative neurodevelopmental outcome data, overall and by PCO2 category
All infants
(n = 265)
Hypocapnic 
(n = 42)
Normocapnic
(n = 176)
Hypercapnic
(n = 46)
p
MDI§ 82 (49 – 120; 249) 86 (49 – 112; 39) 84 (49 – 120; 168) 64 (49 – 116; 41) 0.05
MDI <85 131/249 (53) 19/39 (49) 85/168 (51) 26/41 (63) 0.30
MDI <70 78/249 (31) 11/39 (28) 45/168 (27) 21/41 (51) <0.01
PDI§ 84 (49 – 114; 226) 88 (49 – 114; 33) 84 (49 – 114; 154) 83 (49 – 110; 38) 0.25
PDI <85 118/226 (52) 16/33 (49) 80/154 (52) 21/38 (55) 0.85
PDI <70 75/226 (33) 9/33 (27) 48/154 (31) 17/38 (45) 0.21
Total mortality at follow-up 48/359 (13) 7/57 (12) 20/230 (9) 20/70 (29) <0.01
Hearing impairment§ 13/263 (5) 1/40 (3) 8/177 (5) 3/45 (7) 0.67
Visual impairment 50/264 (19) 7/40 (18) 29/178 (16) 13/45 (29) 0.15
NDI (MDI <70 or PDI <70/hearing or 
visual impairment) 115/233 (49) 16/35 (46) 71/157(45) 27/40 (68) 0.04
NDI or death 163/281 (58) 23/42 (55) 91/177 (51) 47/60 (78) <0.01
GMFCS§
Level 0 133 (50) 18 (43) 92 (52) 23 (49)
0.01
Level 1 89 (34) 19 (45) 61 (35) 9 (19)
Level 2 17 (6) 3 (7) 6 (3) 8 (17)
Level 3 10 (4) 2 (5) 6 (3) 2 (4)
Level 4 13 (5) 0 (0) 9 (5) 4 (9)
Level 5 3 (1) 0 (0) 2 (1) 1 (2)
CDI score†
Percentiles for CDI scores‡
22 (1 – 58; 188)
10 (<2 to >90)
22 (8 – 58; 35)
5 (<2 to >90)
22 (1 – 52; 116)
10 (<2 to >90)
22 (1 – 46; 37)
5 (<2 to >90) 0.24
Weight at follow-up, kg† 10.5 (5.6 – 17.2; 254) 10.1 (7.7 – 17.2; 39) 10.8 (5.6 – 16.0; 171) 10.0 (6.7 – 14.9; 43) 0.01
Height at follow-up, cm† 84 (66 – 102; 253) 84 (73 – 93; 40) 85 (70 – 102; 170) 83 (66 – 92; 42) 0.01
Head circumference, cm† 47 (40 – 52; 253) 46.6 (42.5 – 49; 41) 47 (40 – 51; 168) 46 (43 – 52; 44) 0.11
Corrected age at follow-up, months† 24 (18 – 31; 265) 24 (20 – 29; 42) 24 (18 – 31; 176) 24 (19 – 28; 46) 0.14
The 2 infants with mainly fluctuating PCO2 values were not assigned to any  group; one died and the other survived but was severe-
ly impaired, with MDI <49 and PDI <49. 
Unless otherwise specified, data are given as: n (%), median (range; n); χ2 test. § The Fisher exact test. † The Kruskal-Wallis test. ‡ Ac-
cording to the standard sample: median (range).
MDI, mental developmental index; PDI, psychomotor developmental index; NDI, neurodevelopmental impairment; GMFCS, Gross 
Motor Function Classification System; CDI, Child Development Inventory.
Table 4. Relationship of CRIB scores with common adverse outcomes
Outcome No Yes p
Death or BPD 5 (1, 4, 8, 15), n = 240 8 (1, 7, 9, 16), n = 119 <0.01
IVH (all grades)† 7 (1, 4, 8, 14), n = 227 6 (1, 5, 8, 15), n = 104 0.31
Death or BPD or IVH 5 (1, 4, 7, 14), n = 174 7 (1, 5, 9, 16), n = 185 <0.01
MDI <85 5 (1, 4, 7, 14), n = 118 7 (1, 4, 8, 14), n = 147 <0.01
PDI <85 5 (1, 4, 7, 14), n = 108 7 (1, 4, 8, 14), n = 157 0.01
MDI <70 5 (1, 4, 8, 14), n = 171 7 (1, 6, 8, 14), n = 94 <0.01
PDI <70 6 (1, 4, 8, 14), n = 151 7 (1, 4, 8, 14), n = 114 <0.01
BPD corresponded to moderate/severe BPD according to the consensus definition [20]. CRIB score: median (minimum, 1st quartile, 
3rd quartile, maximum). The Wilcoxon rank sum test was used. CRIB, Clinical Risk Index for Babies.
† The CRIB scores of infants who died before the IVH could be finally evaluated were: 9.5 (4, 7.5, 10.5, 16), n = 28.
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Discussion
In line with our hypothesis, adverse outcomes were 
not evenly distributed, but occurred with greater frequen-
cy in the hypercapnic group, i.e., infants whose maximum 
PCO2 was in the highest quartile of maximum PCO2 on 
most days. The 2 fluctuating infants also had poor out-
comes. This finding aligns well with previously published 
findings indicating that high PCO2 levels may be harmful 
[30]. In the main trial, there was a nonsignificant trend 
towards a higher likelihood of BPD in infants who had 
been randomized into the higher target group [15]. It is 
also consistent with animal [31–33] and cell culture [9, 
10] experiments which indicated potential damage to be 
associated with high PCO2 levels.
While receiving comparable tidal volumes, the hyper-
capnic group required higher MAP × FiO2, indicating 
poorer lung compliance and increased dead-space venti-
lation. Regression analyses revealed that a high MAP × 
FiO2 requirement was, along with birth weight, the most 
predictive for the 2 outcome combinations death/BPD 
and death/BPD/IVH. Apparently, infants who required 
high-pressure ventilation were unable to attenuate higher 
PCO2 values by their own efforts. These infants were sub-
sequently prone to developing chronic lung disease. 
These findings indicate that the degree of severity of an 
individual’s lung disease was the main determinant for 
subsequently developing BPD; this was corroborated by 
the higher CRIB scores for the hypercapnic group and the 
2 fluctuating infants. Therefore, high or fluctuating PCO2 
Table 5. Odds ratios for the risk of moderate-to-severe BPD or death using multiple logistic regression analysis
Difference for
odds ratio
Odds ratio
(95% confidence interval)
p
Gestational age 1 week 0.95 (0.75 – 1.21) 0.68
Birth weight 1 g 0.996 (0.994 – 0.998) <0.001
Sex female/male 0.64 (0.36 – 1.13) 0.13
Average PCO2 exposure 1 mm Hg/h 1.04 (0.98 – 1.11) 0.17
Minimum PCO2 1 mm Hg 1.04 (0.99 – 1.09) 0.13
Maximum PCO2 1 mm Hg 0.99 (0.96 – 1.01) 0.25
Number of days with fluctuating PCO2 1 1.50 (0.90 – 2.50) 0.12
Exposure to MAP × FiO2 (ventilatory intensity) mbar/h 2.29 (1.52 – 3.45) <0.001
PDA yes/no 1.43 (0.69 – 2.95) 0.33
BPD corresponded to moderate or severe BPD according to the consensus definition [20]. 
Table 6. Odds ratios for the risk of the combined outcomes of moderate-to-severe BPD or IVH (any grade) or 
death using multiple logistic regression analysis
Difference for
odds ratio
Odds ratio
(95% confidence interval)
p
Gestational age 1 week 0.87 (0.71 – 1.07) 0.19
Birth weight 1 g 0.999 (0.997 – 1.001) 0.38
Sex female/male 0.84 (0.52 – 1.37) 0.49
Average PCO2 exposure 1 mm Hg/h 1.01 (0.96 – 1.06) 0.81
Minimum PCO2 1 mm Hg 0.97 (0.93 – 1.02) 0.20
Maximum PCO2 1 mm Hg 1.01 (0.99 – 1.03) 0.54
Number of days with fluctuating PCO2 1 0.76 (0.47 – 1.22) 0.25
Exposure to MAP × FiO2 (ventilatory intensity) mbar/h 2.25 (1.49 – 3.42) <0.001
PDA yes/no 1.75 (0.86 – 3.56) 0.12
BPD corresponded to moderate or severe BPD according to the consensus definition [20]. 
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values may not be causally involved in the subsequent de-
velopment of BPD. The large overlap between the PCO2 
groups and the initial randomized assignment to a group 
highlights the difficulty in maintaining preterm infants, 
who have a range of illnesses of varying severity and re-
spiratory effort, within certain target ranges.
The significantly lower MDI scores in the hypercapnic 
group may suggest that poorer neurodevelopmental out-
comes may be associated with a higher PCO2 level. A sim-
ilar association between high or fluctuating PCO2 with 
IVH and neurodevelopmental delays have been found in 
single-center retrospective studies [6, 17]. Two previous 
randomized trials on permissive hypercapnia did not, 
however, reveal an association between randomized 
group assignment and neurodevelopmental outcome [15, 
34], but a third trial demonstrated a significant increase 
in low MDI scores or death associated with hypercapnia 
[30]. Although this result was derived from a secondary 
outcome and the trial was small, it parallels the findings 
presented here, especially as the same component of the 
Bayley test (MDI) was affected.
Our multiple logistic regression analysis did not sup-
port a significant association between PCO2 exposure and 
poor MDI or PDI scores. Poor MDI scores were associ-
ated with birth weight and IVH, and poor PDI scores with 
IVH only, as seen in previous studies [16, 35, 36].
The role of lung disease was also indicated by the as-
sociation of poor MDI and PDI scores with higher CRIB 
scores. More severe lung disease may therefore be the 
most plausible link to neurodevelopmental outcomes, 
Table 7. Odds ratios for the risk of MDI <70 using multiple logistic regression analysis
Difference for
odds ratio
Odds ratio
(95% confidence interval)
p
Gestational age 1 week 1.10 (0.86 – 1.40) 0.46
Birth weight 1 g 0.995 (0.993 – 0.998) <0.0001
Sex female/male 1.45 (0.81 – 2.60) 0.22
Average PCO2 exposure 1 mm Hg/h 1.03 (0.97 – 1.10) 0.32
Minimum PCO2 1 mm Hg 0.97 (0.92 – 1.03) 0.32
Maximum PCO2 1 mm Hg 1.02 (0.99 – 1.04) 0.17
Number of days with fluctuating PCO2 1 0.91 (0.53 – 1.58) 0.75
Exposure to MAP × FiO2 (ventilatory intensity) mbar/h 1.28 (0.78 – 2.10) 0.33
IVH yes/no 2.53 (1.35 – 4.75) 0.004
All factors listed in this table were shown to be statistically significant using univariate regression analysis. 
Table 8. Odds ratios for the risk of PDI <70 using multiple logistic regression analysis
Difference for
odds ratio
Odds ratio
(95% confidence interval)
p
Gestational age 1 week 1.12 (0.89 – 1.41) 0.34
Birth weight 1 g 0.998 (0.996 – 1.000) 0.12
Sex female/male 0.91 (0.53 – 1.57) 0.74
Average PCO2 exposure 1 mm Hg/h 1.00 (0.94 – 1.06) 0.98
Minimum PCO2 1 mm Hg 0.96 (0.91 – 1.01) 0.08
Maximum PCO2 1 mm Hg 1.02 (1.00 – 1.05) 0.05
Number of days with fluctuating PCO2 1 0.80 (0.47 – 1.35) 0.40
Exposure to MAP × FiO2 (ventilatory intensity) mbar/h 1.38 (0.86 – 2.23) 0.19
IVH yes/no 2.79 (1.54 – 5.04) 0.0007
All factors listed in this table were shown to be statistically significant using univariate regression analysis. 
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since there is a clear, established association between BPD 
and poor development [14]. Lung disease has also been 
shown to adversely affect brain integrity in animal ex-
periments [37].
SUPPORT (Surfactant, Positive Pressure, and Oxy-
genation Randomized Trial) enrolled 1,316 infants and 
randomized them to receive continuous positive airway 
pressure (CPAP) with an upper PCO2 limit of 65 mm Hg 
for intubation and extubation, with a strategy of using 
primary intubation, surfactant administration, and an 
upper PCO2 limit of 50 mm Hg [38]. PCO2 data were also 
available and were analyzed in relation to clinical out-
comes [18]. A higher PCO2 was clearly associated with 
death, BPD, IVH, and neurodevelopmental impairment. 
This may result from the much larger sample size, en-
abling even weaker associations to be recognized. It was 
postulated, as in our study, that high PCO2 is a marker of 
disease severity. 
In comparing this and previous analyses of the asso-
ciations between PCO2 and clinical outcomes [6, 17, 18], 
it is important to note the varying definitions used to di-
vide infants into PCO2 groups. In a first step, infants were 
classified according to their PCO2 values on each treat-
ment day and then ultimately assigned according to the 
most days spent in a category. This was done to avoid, for 
example, the classification of an otherwise stable infant 
with only 1 very high PCO2 value on day 12 as hypercap-
nic or fluctuating. Such an infant would be very different 
from one with a high PCO2 on each of the first 7 days of 
life. Our classification resulted in lower proportions of 
infants being classified hypocapnic, hypercapnic, or fluc-
tuating, but our classification was strong as it was based 
on a consistent status over a number of days (Fig. 1). Re-
gardless of this definition, however, the major findings of 
previous studies and ours were similar. 
Limitations of this study include the retrospective de-
sign, based on a dataset from a trial that was not designed 
for this analysis, and the sample size which was not pow-
ered for the outcome parameters investigated. Therefore, 
type I and type II errors cannot be excluded, and all find-
ings must primarily be seen as hypothesis-generating. Fi-
nally, a number of univariate and multiple analyses were 
performed, increasing the likelihood of random differ-
ences. The implications of the follow-up rate and the use 
of the German Bayley II translation have been discussed 
elsewhere [16].
In summary, infants with the highest and longest-last-
ing levels of PCO2 tended to be those with the worst lung 
disease. Higher rates of mortality and BPD are therefore 
probably more related to worse lung disease at the begin-
ning than PCO2 values. PCO2 can thus be viewed as a 
proxy of lung disease severity. It can be assumed that 
these infants were those least able to compensate for re-
ductions in mechanical ventilatory support by their own 
respiratory efforts. The infants in the hypercapnic group 
were also found to have lower MDI scores, but this asso-
ciation was not reproducible in multiple linear regres-
sion analyses. Rather, birth weight and IVH were the 
strongest predictors of neurodevelopmental outcome. 
Our data do not allow us to recommend certain PCO2 
target ranges as desirable for ventilated preterm infants. 
As noted previously, PCO2 targets for ventilated preterm 
infants should be tailored to optimize short-term out-
comes [15, 16, 34].
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